B. Metzler seel. Sohn & Co. AG Purchases 5,322 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B. Metzler seel. Sohn & Co. AG boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 57.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,557 shares of the company’s stock after acquiring an additional 5,322 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in IDEXX Laboratories were worth $6,018,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IDXX. Norges Bank bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $412,258,000. Flossbach Von Storch SE lifted its stake in IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after acquiring an additional 464,791 shares during the period. William Blair Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after acquiring an additional 369,471 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after acquiring an additional 316,048 shares during the period. Finally, Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $113,104,000. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IDXX shares. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Trading Up 1.0 %

IDEXX Laboratories stock opened at $419.95 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The firm has a market capitalization of $34.04 billion, a price-to-earnings ratio of 39.36, a P/E/G ratio of 3.41 and a beta of 1.39. The firm has a 50 day moving average of $437.08 and a 200 day moving average of $442.03.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.